Kevin M. Sullivan, MD, Discusses Treatment Expansion in Lung Cancer
Kevin M. Sullivan, MD, from the Northwell Health Cancer Institute, discussed how the options for treatment of patients with lung cancer have expanded greatly at the Annual New York Lung Cancers Symposium®.
Kevin M. Sullivan, MD, from the Northwell Health Cancer Institute, discussed how the options for treating patients with lung cancer have expanded in the past several years at the Annual New York Lung Cancers Symposium®.
Transcription:
There’s a lot of exciting things about being a thoracic medical oncologist. The options for treating our patients have expanded so greatly in the past several years and it’s an exciting time as just, it seems like every day, just more and more information is coming out about ways to not only diagnose and work up our patients, but to find the most appropriate treatment that has the highest chance of success in treating our patients. And even those patients that develop resistance that progress on a certain therapy, we have more and more options for them coming down the line, so it’s an exciting time to be able to help and benefit our patients.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
